422 related articles for article (PubMed ID: 16818498)
1. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
2. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.
Nitiss KC; Malik M; He X; White SW; Nitiss JL
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):8953-8. PubMed ID: 16751265
[TBL] [Abstract][Full Text] [Related]
3. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.
Rogojina AT; Nitiss JL
J Biol Chem; 2008 Oct; 283(43):29239-50. PubMed ID: 18723844
[TBL] [Abstract][Full Text] [Related]
5. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks.
Sabourin M; Nitiss JL; Nitiss KC; Tatebayashi K; Ikeda H; Osheroff N
Nucleic Acids Res; 2003 Aug; 31(15):4373-84. PubMed ID: 12888496
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; Koyama H
DNA Cell Biol; 2005 Jun; 24(6):388-93. PubMed ID: 15941391
[TBL] [Abstract][Full Text] [Related]
8. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
de Campos-Nebel M; Larripa I; González-Cid M
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824055
[TBL] [Abstract][Full Text] [Related]
11. Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.
Stantial N; Rogojina A; Gilbertson M; Sun Y; Miles H; Shaltz S; Berger J; Nitiss KC; Jinks-Robertson S; Nitiss JL
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26876-26884. PubMed ID: 33046655
[TBL] [Abstract][Full Text] [Related]
12. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
13. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
14. Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II.
Baldwin EL; Berger AC; Corbett AH; Osheroff N
Nucleic Acids Res; 2005; 33(3):1021-30. PubMed ID: 15718301
[TBL] [Abstract][Full Text] [Related]
15. DNA repair functions that control sensitivity to topoisomerase-targeting drugs.
Malik M; Nitiss JL
Eukaryot Cell; 2004 Feb; 3(1):82-90. PubMed ID: 14871939
[TBL] [Abstract][Full Text] [Related]
16. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
17. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
18. Effects of HDF1 (Ku70) and HDF2 (Ku80) on spontaneous and DNA damage-induced intrachromosomal recombination in Saccharomyces cerevisiae.
Cervelli T; Galli A
Mol Gen Genet; 2000 Sep; 264(1-2):56-63. PubMed ID: 11016833
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.
Nitiss J; Wang JC
Proc Natl Acad Sci U S A; 1988 Oct; 85(20):7501-5. PubMed ID: 2845409
[TBL] [Abstract][Full Text] [Related]
20. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]